ABSTRACT
Introduction Rapid sequence induction (RSI) is widely used in paediatric anaesthesia. Concerns over complications associated with classical RSI have prompted the exploration of alternatives. This study was conducted to determine the feasibility and safety of using bolus remifentanil in combination with a hypnotic agent for paediatric RSI.
Methods This proof-of-concept study analysed data from paediatric patients, with at least one risk factor for pulmonary aspiration, undergoing RSI with remifentanil at the Montpellier University Hospital between December 2021 and August 2023. Exclusion criteria included the planned use of a neuromuscular blocking agent for RSI, preoperative hypoxemia, hemodynamic shock or difficult intubation risk factors. Remifentanil was administered by direct intravenous injection with optional prophylactic administration of atropine. Data on intubation success rates, major and minor complications and rescue treatment were collected and analysed.
Results The study included 267 children with a mean age of 7.8 +/- 4.4 years. The success rate for the first intubation attempt was 92.9% (95% CI, 88.9-95.6). No major complication or pulmonary aspiration was reported. Minor complications, primarily hypotension, occurred in 15.7% of patients. The prophylactic use of atropine was correlated with a reduction in minor complications.
Discussion This study supports the use of remifentanil for RSI in a selected paediatric population. Remifentanil offers good intubation conditions with a high success rate at the first attempt and a high safety profile with no major complication reported. Prophylactic atropine administration seems beneficial in reducing minor complications. These findings advocate for integrating remifentanil as an alternative in protocols for modified RSI. Further randomised studies are required to validate such outcomes and refine clinical approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by an institutional review board in April 2022 (IRB Montpellier University Hospital — IRB-MTP_2022_04_202201075).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
